HOME >> BIOLOGY >> NEWS
Joslin Diabetes Center in Boston establishes first affiliate in Canada

BOSTON-October 19, 2006-Joslin Diabetes Center, the global leader in diabetes research, care and education, has announced its partnership with Acadie-Bathurst Health Authority (ABHA) in New Brunswick, Canada. The new affiliate, which is located at Chaleur Regional Hospital, is Joslin's first Canadian Affiliate.

The new Joslin Affiliate is an Education Affiliate, so all of Joslin's premier education programs and services are shared with the institution. This will complement the endocrine services offered by Dr. Farrukh Khan a board-certified endocrinologist who serves as medical director.

"There is no doubt in my mind that the establishment of a Joslin Diabetes Center Education Affiliate right here in Bathurst is a major coup for residents of the region and the entire population of New Brunswick," stated Gabriel Godin, chair of the ABHA board of trustees.

"According to the Canadian Diabetes Association, more than 5.4 percent of the people in New Brunswick have diabetes, and as many as one-third of the population has diabetes but don't know they have the disease," said Judith Eyres Goodwin, director of Joslin's Affiliated Centers Program. "We look forward to working with the professionals at Chaleur Regional Hospital to bring Joslin's integrated, state-of-the-art education programs and services to people with diabetes and related conditions in the region."

"Our staff have received training from Joslin Diabetes Center in Boston to ensure that they follow the organization's standards closely in providing education to patients with diabetes in the Chaleur region and the Acadian Peninsula," said Alice Hbert, director of nursing for the ABHA.


'"/>

Contact: Jenny Eriksen
jenny.eriksen@joslin.harvard.edu
617-732-2415
Joslin Diabetes Center
19-Oct-2006


Page: 1

Related biology news :

1. Joslin study indicates insulin receptors play a critical role in promoting islet growth
2. Joslin researchers discover a surprising culprit in the search for causes of diabetic birth defects
3. Joslin study reveals how a specific fat type can protect against weight gain and diabetes
4. Joslin discovers protein that causes blood vessel leakage and swelling with diabetic retinopathy
5. Joslin-led study uncovers role of appetite hormone MCH in insulin production
6. Joslin Diabetes Center study examines insulin pump therapy in adolescents
7. Walgreens and Joslin Diabetes Center form broad alliance to improve diabetes outcomes
8. Joslin awards Victory Medal to New York man living 75 years with type 1 diabetes
9. Joslins new book demystifies nutrition and meal planning for people with diabetes
10. Joslin study refutes recent report that bone marrow can replenish female oocytes
11. Joslin discovers signs of residual islet cell function in people with long-term type 1 diabetes

Post Your Comments:
(Date:10/16/2014)... Melbourne researchers have challenged conventional thinking on how the ... new mechanism for how bowel cancer starts. , The ... maintaining and regenerating the ,crypts, that are a feature ... are involved in bowel cancer development, a controversial finding ... existence. , Using 3D imaging technologies, Dr Chin Wee ...
(Date:10/16/2014)... Respiratory Syncytial Virus causes severe respiratory tract infections ... each year. Scientists at VIB and Ghent University ... to counteract this common virus infection. , ... strategy that paves the way for the development ... a virus that causes suffering in numerous small ...
(Date:10/16/2014)... -- NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market announces that ... Smart Wallet, at the 13 th annual Future ... conference on the intersection of technology and the economy. ... founder and publisher of the Strategic News Service™, the ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2New perspectives for development of an RSV vaccine 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
(Date:10/22/2014)... BOSTON , Oct. 22, 2014  Actavis plc ... pharmaceutical company, and Rhythm, a biopharmaceutical company, today announced ... acquire Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., which ... the treatment of diabetic gastroparesis and other GI functional ... Phase 2 trial of relamorelin for the treatment of ...
(Date:10/22/2014)... 2014 WriteResult, LLC – a ... been working with a team of researchers from Yale ... Community Farming Collaborative to provide electronic questionnaire data collection ... study, which started in May, aims to evaluate the ... weekly exposure to and participation in urban agriculture to ...
(Date:10/22/2014)... 22, 2014   Synthetic Biologics, Inc. (NYSE ... for serious infections and diseases, announced today that the ... of Allowance for a composition of matter patent application ... program, SYN-004. This is Synthetic Biologics, first allowed ... and adds to the Company,s extensive C. difficile ...
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market ... Labeling Systems, Table-top Counters) by End-user (Inpatient Pharmacy ... Trends to 2019” analyzes and studies the major ... Europe, Asia-Pacific, and the Rest of the World ... figures spread through 300 pages and in-depth TOC ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4
Cached News: